[Skip to Content]
[Skip to Content Landing]
From The Medical Letter on Drugs and Therapeutics
May 15, 2018

Abuse-Deterrent Opioids

JAMA. 2018;319(19):2036-2037. doi:10.1001/jama.2018.4996

Development of abuse-deterrent opioid products, including reformulation of existing products, has become a priority for drug manufacturers and public health advocates. Since our last article on this subject,1 several new abuse-deterrent opioid formulations (Table) have been approved by the FDA,2,3 including an oxycodone tablet formulation (Roxybond – Inspirion) that is the first immediate-release opioid product FDA-approved to include claims of abuse deterrence in its labeling.4 No opioid formulation prevents consumption of a large number of intact dosage units, the most common method of abuse. Abuse-deterrent formulations have one or more properties that make their intentional nontherapeutic use more difficult, less attractive, or less rewarding.5